• February 15, 2017
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the company a license for Stronghold® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats. Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation inmore...
  • December 21, 2016
    PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a license for CYTOPOINT™, the first monoclonal antibody (mAb) therapy approved to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs. CYTOPOINT targets and neutralizes interleukin-31 (IL-31), a key protein involved in triggering itch in dogs. It provides fast, effective relief of itchingmore...
  • August 8, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of Scandinavian Micro Biodevices, a pioneer in developing and manufacturing microfluidic “lab on a chip” diagnostic analyzers and tests for veterinary point-of- care services for $80 million. The acquisition adds to Zoetis’ complementary point-of-care diagnostics portfolio, giving the company an expanded and promising pipeline in this fast-growing segment ofmore...
  • May 31, 2016
    Zoetis scientists will present six abstracts at the 8th World Congress of Veterinary Dermatology (WCVD) that contribute to the body of evidence supporting the use of lokivetmab, an antibody designed specifically for dogs that inhibits the canine cytokine interleukin-31 (cIL-31). The data also advance scientific understanding of the role of IL-31 in canine atopic dermatitis. The WCVD takes place May 31 to June 4 in Bordeaux, France.Data Supporting the Efficacy of Lokivetmab in Canine Atopicmore...
  • May 16, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Dogs that experience fear and anxiety in response to loud noise such as fireworks, thunder, and construction work now have a new treatment option with the launch of SILEO® (dexmedetomidine oromucosal gel), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for treatment of noise aversion in dogs. Noise aversion refers to the behavioral and clinical signs of fear and anxiety experienced by dogs in response tomore...
  • April 28, 2016
    GUILDFORD, SURREY, UK - April 27, 2016 - Zoetis and the University of Surrey today launched the Veterinary Health Innovation Engine (vHive), a novel multi-disciplinary centre designed to promote the development and adoption of digital innovation in animal health.Digital technologies including wearables, apps, sensors and satellites promise to transform real-time information capture for animal owners and their veterinary advisors.  This will enable improved understanding of animal healthmore...
  • February 25, 2016
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved SimparicaTM (sarolaner) Chewables to kill adult fleas and prevent flea infestations, as well as treat and control tick infestations due to the Lone Star tick, the Gulf Coast tick, the American dog tick, and the brown dog tick. Simparica is approved for use in dogs 6 months of age or older and weighing 2.8 pounds or more. In a single-dose, tastymore...
  • November 17, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted marketing authorization for SimparicaTM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica givesmore...
  • August 5, 2015
    Sydney, New South Wales, Australia - August 5, 2015 – Zoetis today announced that the Hendra virus vaccine,Equivac® HeV, has received registration from the Australian Pesticides and Veterinary Medicines Authority (APVMA).“We at Zoetis are pleased that after nearly three years of positive uptake, Equivac® HeV vaccine has successfully been registered,” said Lance Williams, General Manager for Zoetis in Australia and New Zealand.  “The APVMA undertakes one of the most detailedmore...
  • August 3, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientificmore...